Exelixis Inc reaches 20-day high amid market strength
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 22 Dec 25
Source: Coinmarketcap
Exelixis Inc's stock price increased by 4.37%, reaching a 20-day high, supported by positive movements in the broader market, with the Nasdaq-100 up 0.35% and the S&P 500 up 0.62%.
This rise is attributed to sector rotation, as the company is not directly impacted by any recent news. The overall market strength has provided a favorable environment for stocks like Exelixis Inc, which are benefiting from the positive sentiment in the market.
The implications of this price movement suggest that investors are optimistic about the stock's potential, reflecting a broader trend of confidence in the market, which may lead to further gains in the near future.
Analyst Views on EXEL
Wall Street analysts forecast EXEL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EXEL is 44.09 USD with a low forecast of 30.00 USD and a high forecast of 52.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Analyst Rating
7 Buy
8 Hold
1 Sell
Moderate Buy
Current: 42.660
Low
30.00
Averages
44.09
High
52.00
Current: 42.660
Low
30.00
Averages
44.09
High
52.00
About EXEL
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
